Oyster Point Pharma Stock Forecast, Price & News

+0.02 (+0.10 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume70,133 shs
Average Volume75,287 shs
Market Capitalization$499.30 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OYST News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

Oyster Point Pharma logo

About Oyster Point Pharma

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.07 out of 5 stars

Medical Sector

1071st out of 2,100 stocks

Biological Products, Except Diagnostic Industry

146th out of 198 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Oyster Point Pharma (NASDAQ:OYST) Frequently Asked Questions

Is Oyster Point Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oyster Point Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oyster Point Pharma stock.
View analyst ratings for Oyster Point Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Oyster Point Pharma?

Wall Street analysts have given Oyster Point Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oyster Point Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Oyster Point Pharma's next earnings date?

Oyster Point Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Oyster Point Pharma

How were Oyster Point Pharma's earnings last quarter?

Oyster Point Pharma, Inc. (NASDAQ:OYST) released its earnings results on Thursday, May, 6th. The company reported ($0.73) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.91) by $0.18.
View Oyster Point Pharma's earnings history

How has Oyster Point Pharma's stock price been impacted by COVID-19?

Oyster Point Pharma's stock was trading at $31.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OYST stock has decreased by 38.6% and is now trading at $19.22.
View which stocks have been most impacted by COVID-19

Who are Oyster Point Pharma's key executives?

Oyster Point Pharma's management team includes the following people:
  • Dr. Jeffrey Nau Ph.D., MMS, Pres, CEO & Director (Age 46, Pay $833.6k)
  • Mr. Daniel Lochner M.B.A., Chief Financial Officer (Age 38, Pay $644.68k)
  • Mr. John Snisarenko M.B.A., Chief Commercial Officer (Age 57, Pay $604.68k)
  • Mr. George Donato, Sr. VP of CMC & Operations
  • Dr. Eric Carlson Ph.D., Chief Scientific Officer
  • Ms. Jill Andersen, Gen. Counsel & Chief Compliance Officer
  • Ms. Dawn Pruitt Koffler M.B.A., VP of Marketing
  • Ms. Nicolette Sherman, Chief HR Officer
  • Ms. Loni Da Silva, Sr. VP of Regulatory Affairs
  • Dr. Marian Macsai M.D., Chief Medical Officer of Medical Affairs

Who are some of Oyster Point Pharma's key competitors?

What other stocks do shareholders of Oyster Point Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), The Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), (NGM), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT).

When did Oyster Point Pharma IPO?

(OYST) raised $85 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray served as the underwriters for the IPO.

What is Oyster Point Pharma's stock symbol?

Oyster Point Pharma trades on the NASDAQ under the ticker symbol "OYST."

Who are Oyster Point Pharma's major shareholders?

Oyster Point Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (7.16%), BlackRock Inc. (2.84%), Oak Ridge Investments LLC (2.24%), GW&K Investment Management LLC (1.55%), First Manhattan Co. (1.43%) and Citadel Advisors LLC (0.89%). Company insiders that own Oyster Point Pharma stock include Clare Ozawa, Daniel Lochner, Healthcare Strategic Growt Kkr, Jeffrey Nau, John Snisarenko and Vida Ventures, Llc.
View institutional ownership trends for Oyster Point Pharma

Which institutional investors are selling Oyster Point Pharma stock?

OYST stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Citadel Advisors LLC, Millennium Management LLC, Morgan Stanley, HighTower Advisors LLC, Northern Trust Corp, Bank of New York Mellon Corp, and Alliancebernstein L.P..
View insider buying and selling activity for Oyster Point Pharma
or view top insider-selling stocks.

Which institutional investors are buying Oyster Point Pharma stock?

OYST stock was purchased by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, BlackRock Inc., First Manhattan Co., GW&K Investment Management LLC, JPMorgan Chase & Co., Price T Rowe Associates Inc. MD, HarbourVest Partners LLC, and Geode Capital Management LLC. Company insiders that have bought Oyster Point Pharma stock in the last two years include Clare Ozawa, Daniel Lochner, Healthcare Strategic Growt Kkr, Jeffrey Nau, John Snisarenko, and Vida Ventures, Llc.
View insider buying and selling activity for Oyster Point Pharma
or or view top insider-buying stocks.

How do I buy shares of Oyster Point Pharma?

Shares of OYST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oyster Point Pharma's stock price today?

One share of OYST stock can currently be purchased for approximately $19.22.

How much money does Oyster Point Pharma make?

Oyster Point Pharma has a market capitalization of $499.30 million. The company earns $-70,520,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Oyster Point Pharma have?

Oyster Point Pharma employs 62 workers across the globe.

What is Oyster Point Pharma's official website?

The official website for Oyster Point Pharma is

Where are Oyster Point Pharma's headquarters?

Oyster Point Pharma is headquartered at 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540.

How can I contact Oyster Point Pharma?

Oyster Point Pharma's mailing address is 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540. The company can be reached via phone at 609-382-9032 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.